VTGN News and Press, VistaGen Therapeutics Inc. From 06/16/23

Vistagen Therapeutics (NASDAQ: VTGN) CEO Shawn Singh will participate in this month’s Healthcare Virtual Conference presented by Maxim Group LLC. The three-day online event is scheduled for June 20–22, 2023, and will be hosted on the M-Vest platform. Vistagen is a late clinical-sta...

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that its Chief Executive Officer, Shawn Singh, will participate in...

Vistagen Therapeutics (NASDAQ: VTGN) , a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has received notification that the European Patent O...

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that the European Patent Office (EPO) issued an intention to gr...

2023-06-09 10:07:38 ET Gainers: Sientra ( SIEN ) +65% . ContraFect ( CFRX ) +47% . Societal CDMO ( SCTL ) +20% . Akili ( AKLI ) +14% . Erasca ( ERAS ) +12% . Losers: Elevation Oncology ( ELEV ) -41% . Longboar...

Vistagen (NASDAQ: VTGN) , a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, today announced that PH80, one of the company’s five inves...

2023-06-07 09:46:39 ET Vistagen ( NASDAQ: VTGN ) announced Wednesday that its nasal spray therapy PH80 led to a statistically significant efficacy compared to placebo in a mid-stage real-world study as an acute therapy for hot flashes. Citing data from an exploratory Phase 2A st...

PH80 nasal spray demonstrates statistically significant efficacy versus placebo in exploratory double-blind, placebo-controlled Phase 2A study (n=36) in women diagnosed with menopausal hot flashes PH80 was safe and well-tolerated with an adverse event profile similar to placebo ...

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that its Chief Executive Officer, Shawn Singh, will present and ho...

2023-06-06 11:33:12 ET Vistagen ( NASDAQ: VTGN ) to implement a stockholder-approved a one-for-thirty reverse stock split of its outstanding shares of common stock, effective June 7, 2023. The primary corporate and strategic objectives for reverse split is to re...